#### (19) World Intellectual Property Organization International Bureau



## 

(43) International Publication Date 6 May 2005 (06.05.2005)

#### PCT

# (10) International Publication Number

(51) International Patent Classification7:

A61K

WO 2005/039481 A2 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,

(21) International Application Number:

PCT/IN2004/000192

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,

ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,

FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,

- (22) International Filing Date: 30 June 2004 (30.06.2004)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

987/MUM/2003 19 September 2003 (19.09.2003)

(71) Applicant (for all designated States except US): SUN PHARMACEUTICAL INDUSTRIES LIMITED [IN/IN]; ACME Plaza, Andheri-Kurla Road, Andheri (East), Mumbai 400059 (IN).

(71) Applicants and

- (72) Inventors: DHARMADHIKARI, Nitin, Bhalachandra [IN/IN]; 17/1, Mahal Industrial Estate, Off Mahakali Caves Road, Andheri (East), Mumbai 400093 (IN). ZALA, Yashoraj, Rupsinh [IN/IN]; 17/1, Mahal Industrial Estate, Off Mahakali Caves Road, Andheri(East), Mumbai 400093 (IN). SINGH, Amarjit [IN/IN]; ACME Plaza, Andheri-Kurla Road, Andheri (East), Mumbai 400059 (IN).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG. PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,

Declarations under Rule 4.17:

GW, ML, MR, NE, SN, TD, TG).


- as to the identity of the inventor (Rule 4.17(i)) for all designations
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations
- as to applicant's entitlement to apply for and be granted a
- patent (Rule 4.17(ii)) for all designations as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations as to the applicant's entitlement to claim the priority of the
- earlier application (Rule 4.17(iii)) for all designations as to the applicant's entitlement to claim the priority of the
  - earlier application (Rule 4.17(iii)) for all designations of inventorship (Rule 4.17(iv)) for US only

### Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ORAL DRUG DELIVERY SYSTEM



(57) Abstract: The present invention provides an oral drug delivery system comprising (a). a core comprising an active ingredient composition comprising at least one active ingredient and pharmaceutically acceptable excipient, and (b). a coating

surrounding the core, wherein the drug delivery system is designed in a manner such that the coating is reliably removed fully or partially from one or more preselected surfaces of the system upon contact with an aqueous environment, provided further that the coating is not removed from at least one of the surfaces. coating is not removed from at least one of the surfaces.

2005/039481 A2